Recent Quotes (30 days)

You have no recent quotes
chg | %

Lannett Company, Inc.  

(Public, NYSE:LCI)   Watch this stock  
Find more results for LCI
23.95
0.00 (0.00%)
Nov 17 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 23.50 - 24.20
52 week 14.90 - 27.90
Open 23.80
Vol / Avg. 446,449.00/900,277.00
Mkt cap 902.13M
P/E 21.40
Div/yield     -
EPS 1.12
Shares 37.67M
Beta 2.73
Inst. own 100%
Jan 30, 2018
Q2 2018 Lannett Company Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Jan 18, 2018
Lannett Company Inc Annual Shareholders Meeting (Estimated) - 9:00AM EST - Add to calendar
Nov 15, 2017
Lannett Company Inc at Jefferies Global Healthcare Conference
Nov 6, 2017
Q1 2018 Lannett Company Inc Earnings Call - Webcast
Nov 6, 2017
Q1 2018 Lannett Company Inc Earnings Release
Aug 23, 2017
Q4 2017 Lannett Company Inc Earnings Call - Webcast
Aug 23, 2017
Q4 2017 Lannett Company Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin 8.56% -0.09%
Operating margin 26.25% 13.56%
EBITD margin - 38.45%
Return on average assets 3.30% -0.03%
Return on average equity 9.35% -0.10%
Employees 1,126 -
CDP Score - -

Address

9000 State Rd
PHILADELPHIA, PA 19136-1615
United States - Map
+1-215-3339000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company's products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Officers and directors

Jeffrey Farber Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Arthur P. Bedrosian J.D. Chief Executive Officer, Director
Age: 71
Bio & Compensation  - Reuters
Martin P. Galvan CPA Chief Financial Officer, Vice President - Finance, Treasurer
Age: 65
Bio & Compensation  - Reuters
John Kozlowski Corporate Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Robert Ehlinger Vice President - Logistics, Chief Information Officer
Age: 58
Bio & Compensation  - Reuters
Samuel H. Israel Vice President, General Counsel, Chief Legal Officer
Age: 55
Bio & Compensation  - Reuters
Kevin R. Smith Vice President - Sales and Marketing
Age: 57
Bio & Compensation  - Reuters
John M. Abt Vice President - Quality
Age: 52
Bio & Compensation  - Reuters
David Drabik Lead Independent Director
Age: 49
Bio & Compensation  - Reuters
Patrick G. LePore Independent Director
Age: 62
Bio & Compensation  - Reuters